NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on NewAmsterdam Pharma Company (NAMS), Insmed (INSM) an...

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Shattuck Labs (STTK) and NewAmsterdam Pharma Company...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on NewAmsterdam Pharma Company yesterday and set a price target of $52.00. Pantgin...

Current Quarter	$-0.47	Next Quarter	$-0.48
Current Year	$-1.76	Next Year	$-1.14
QoQ Growth	-2.1%	YoY Growth	+35.2%
3Y EPS CAGR	-21.5%	Target Price	$50.92
Consensus	Buy	Upside	+40.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NAMS	$36.35	+0.66%	628.52K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NAMS	$36.35	+0.7%	628.52K
3
4
5
6

NAMS

NAMS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get NewAmsterdam Pharma Company N.V. Data in Excel

Get NewAmsterdam Pharma Company N.V. Data in Excel